Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [213]

PLEIADES: Daratumumab combinations for multiple myeloma

Dr Ajai Chari - Mount Sinai, New York City, USA

PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory...

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

Treatment options for high risk relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

BCMA: A new biomarker for multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Transitioning from bortezomib to ixazomib in patients with multiple myeloma

Dr Habte Yimer - Texas Oncology, Tyler, USA

Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )

Implementing national cancer control plans

Dr Eduardo Cazap and Dr Lisa Stevens

Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )

Chemoimmunotherapy or BTK inhibition for patients with CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )

Blinatumomab for relapsed/refractory Burkitt's lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

$Blinatumomab for relapsed/refractory Burkitt's lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )$

Using bioinformatics and genomics to treat AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

More from ecancer